ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy
Autor: | Joseph J Johnson, Christopher L. Cubitt, Anthony M. Magliocco, Yin Xiong, Ardeshir Hakam, Douglas C. Marchion, Ozlen Saglam, Daryoush Saeed-Vafa, Robert M. Wenham, Carolina Strosberg |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Receptor ErbB-4 Microarray endocrine system diseases Cell Survival medicine.medical_treatment Article Carboplatin Immunoenzyme Techniques 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Biomarkers Tumor Tumor Cells Cultured Neoplasm Humans Cystadenocarcinoma Aged Neoplasm Staging Cisplatin Ovarian Neoplasms Chemotherapy business.industry Hematology General Medicine medicine.disease female genital diseases and pregnancy complications Cystadenocarcinoma Serous 030104 developmental biology chemistry Drug Resistance Neoplasm 030220 oncology & carcinogenesis Case-Control Studies Immunohistochemistry Female Ovarian cancer business medicine.drug |
Zdroj: | Cancer Control |
ISSN: | 1526-2359 |
Popis: | Few data exist on the prognostic and predictive impact of erb-b2 receptor tyrosine kinase 4 (ERBB4) in ovarian cancer. Thus, we evaluated ERBB4 expression by immunohistochemistry in a tumor microarray consisting of 100 ovarian serous carcinoma specimens (50 complete responses [CRs] and 50 incomplete responses [IRs] to platinum-based therapy), 51 normal tissue controls, and 16 ovarian cancer cell lines. H scores were used to evaluate expression and were semiquantitatively classified into low, intermediate, and high categories. Category frequencies were compared between tumor specimens vs controls using an unpaired t test. Among tumors, category frequencies were compared between CR and IR to chemotherapy. Overall survival (OS) was stratified by category. In total, 74 ovarian serous carcinoma samples (32 CRs and 42 IRs), 28 normal controls, and 16 ovarian cancer cell lines were evaluable. High-level ERBB4 expression was observed at a significantly higher frequency in ovarian serous carcinoma compared with normal control tissue. Among tumor specimens, ERBB4 expression was significantly higher for those with an IR to chemotherapy compared with CR (P = .033). OS was inversely correlated with ERBB4 expression levels. Median rates of OS were 18, 22, and 58 months among high-, intermediate-, and low-expression tumors, respectively. Our results indicate that ERBB4 expression by immunohistochemistry may correlate with chemotherapy-resistant ovarian serous carcinoma and shortened OS. |
Databáze: | OpenAIRE |
Externí odkaz: |